Foundation Medicine (FMI) Tops Q4 EPS by 12c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Rubrik (RBRK) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY27 EPS Guidance
Leerink Partners Reiterates Market perform After Foundation Medicine (FMI) Reports Weak 2016 Guidance
February 24, 2016 9:35 AM ESTLeerink Partners reiterated a Market Perform rating on Foundation Medicine (NASDAQ: FMI), and cut the price target to $15.00 (from $27.00), following the company's 4Q earnings report. FMI reported 4Q revenue of $26.1M, above the Street's $25.1M estimate. 2016 revenue guidance of $110M-$120M was ~10%/6% below consensus at... More
